Regeneron : FDA Extends Review Period For Dupixent As COPD Treatment By Three Month
31/5 07:18
(RTTNews) - The U.S. Food and Drug Administration has extended by three months the target action date of its priority review of the supplemental Biologics License Application or sBLA for Dupixent (dupilumab) as an add-on maintenance treatment in certain adult patients with uncont...